GlycoVaxyn

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has licensed its quadrivalent bioconjugate shigellosis vaccine candidate to Switzerland’s LimmaTech Biologics for further development and commercialization. This strategic move builds upon GSK’s acquisition of LimmaTech’s predecessor company, GlycoVaxyn, in 2015, which included the vaccine in its portfolio. Phase I/II Development and Multivalent…